Department:Cardiology
Medical School:Fudan University, China
Academic Rank:Associate Chief Physician
Dr. Ma mainly focuses on the clinical management of heart failure and its underlying molecular mechanisms:
1. Diagnosis and treatment of atherosclerotic cardiovascular disease
2. Cardiac arrhythmias and therapy
3. Heart failure management, including pharmacological and device-based therapy
4. Cardiac regeneration, metabolic reprogramming
Natural Science Award of Zhejiang Province, First Prize (Second place), 2023
Cardiovascular Research Award of Young Doctors in Zhejiang Province, 2020
Award for Early Career Investigator, International Society for Heart Research, 2019
Award for Big Data Workshop of Translational Omics Research, Purdue University/NIH, 2017
Zhejiang Scientific and Technological Progress Award, First Prize (Third place), 2013
Fellow, American College of Cardiology, 2022
Member, Bioactive Small Molecule Professional Committee of the Chinese Pathophysiology Society, 2022
Youth Committee Member, Cardiovascular Branch of Zhejiang Medical Association, 2021
Executive Director, Zhejiang University Young Professor Association, 2019
Member, Council on Basic Cardiovascular Science, American Heart Association, 2018
Member, International Society for Heart Research (ISHR), 2018
Member, Zhejiang Medical Association (Cardiovascular Tissue Repair and Regeneration), 2018
Ph.D., Fudan University, Zhongshan Hospital, 2007-2010
Dr. Ma mainly focuses on heart failure and its underlying molecular mechanisms: 1) Cardiac metabolic reprogramming, regulation, and roles in heart failure; 2) Direct reprogramming to mend a broken heart; 3) Translational research using multi-disciplinary means. He was awarded as Outstanding Youth Science Foundation, Distinguished Young Scholar of Zhejiang Province, Young Committee Member of Zhejiang Society of Cardiology. He has published over 60 articles in Nature, Circulation, Cardiovascular Research (Editor's Choice), Hypertension (High Impact Paper) etc.
Hong Ma, Shuo Yu, Xiaojing Liu, Yingao Zhang, Thomas Fakadej, Ziqing Liu, Chaoying Yin, Weining Shen, Jason W. Locasale, Joan M. Taylor, Li Qian*, Jiandong Liu*. Lin28a Regulates Pathological Cardiac Hypertrophic Growth through Pck2-mediated Enhancement of Anabolic Synthesis. Circulation. 2019 Apr 2,139(14):1725-1740.
Ziqing Liu#, Li Wang#, Joshua D. Welch#, Hong Ma, Yang Zhou, Haley Ruth Vaseghi, Shuo Yu, Joseph Blake Wall, Sahar Alimohamadi, Michael Zheng, Chaoying Yin, Weining Shen, Jan F Prins, Jiandong Liu*, Li Qian*. Single-cell transcriptomics reconstructs fate conversion from fibroblast to cardiomyocyte. Nature. 2017 Nov 2; 551(7678):100-104.
Hong Ma, Li Wang, Chaoying Yin, Jiandong Liu, and Li Qian. In vivo cardiac reprogramming using an optimal single polycistronic construct. Cardiovasc Res. 2015 Nov 1;108(2):217-9. Editor's Choice
Role of Serine Metabolic Enzyme PSAT1 on Cardiac Hypertrophy via RNA Methylation (Principle Investigator). Funding Source: National Natural Science Foundation of China.
Glutamate Metabolism in Heart Failure (Principle Investigator). Funding Source: National Natural Science Foundation of China.
Role of RNA binding Protein PTBP1 in Cardiac Hypertrophy (Principle Investigator). Funding Source: National Natural Science Foundation of China.
Role of PTBP1 in Heart Failure after Myocardial Infarction (Principle Investigator). Funding Source: Natural Science Foundation of Zhejiang Province.